JS-K
JS-K结构式
|
常用名 | JS-K | 英文名 | JS-K |
|---|---|---|---|---|
| CAS号 | 205432-12-8 | 分子量 | 384.30200 | |
| 密度 | 1.606g/cm3 | 沸点 | 546.692ºC at 760 mmHg | |
| 分子式 | C13H16N6O8 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 284.429ºC |
|
N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia.
Macromol. Biosci. 16 , 121-8, (2016) There is a need for new treatment strategies of acute myeloid leukemia (AML). In this study, four different drugs, including cytarabine, daunorubicin, GDC-0980, and JS-K, were investigated in vitro for the two-drug combinations treatment of AML. The results r... |
|
|
Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
Redox Biol. 1 , 115-24, (2013) JS-K is a nitric oxide (NO)-releasing prodrug of the O (2)-arylated diazeniumdiolate family that has demonstrated pronounced cytotoxicity and antitumor properties in a variety of cancer models both in vitro and in vivo. The current study of the metabolic acti... |
|
|
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
BMC Cancer 12 , 130, (2012) Nitric oxide (NO) and its oxidative reaction products have been repeatedly shown to block steroid receptor function via nitrosation of zinc finger structures in the DNA-binding domain (DBD). In consequence NO-donors could be of special interest for the treatm... |